3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Urologic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Interventions
Ipilimumab
101
pembrolizumab
94
Nivolumab
87
Cyclophosphamide
69
fludarabine phosphate
55
aldesleukin
52
Interleukin-2
39
Dacarbazine
35
Vemurafenib
31
fludarabine
30
trametinib
29
dabrafenib
29
Temozolomide
28
Whole-Body Irradiation
21
Aminolevulinic Acid
21
Carboplatin
20
CTLA-4 Antigen
20
Bevacizumab
20
Radiotherapy
19
Peripheral Blood Stem Cell Transplantation
19
Radiosurgery
18
Tacrolimus
17
Mycophenolic Acid
17
Paclitaxel
16
HhAntag691
16
3-ingenyl angelate
16
Busulfan
15
Introns
14
Antilymphocyte Serum
14
encorafenib
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
GSK-3326595
×
Dermatologic
×
Clear all
NCT02783300
2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1
Completed
297 enrolled
76 charts